Speaking Engagements
Direct or indirect identification of cancer therapeutic targets
Rafael Rosell M.D PhD
5th Diagnostic Days
Bonn, Germany, October 2011
(Invited lecture)
Personalized therapy in lung cancer
Rafael Rosell M.D PhD
ECCO-ESMO European Multidisciplinary Cancer Congress (EMCC)
Stockholm, Sweden, September 2011
(Invited lecture)
New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways
Rafael Rosell M.D PhD
ECCO-ESMO European Multidisciplinary Cancer Congress (EMCC)
Stockholm, Sweden, September 2011
(Invited lecture, Hamilton Fairley Award)
BRCA1 and astrocyte elevated gene-1 (AEG-1) expression and outcome of erlotinib-treated non-small-cell lung cancer patients harboring epidermal growth factor receptor (EGFR) mutations
Miquel Tarón PhD
ECCO-ESMO European Multidisciplinary Cancer Congress (EMCC)
Stockholm, Sweden, September 2011
(Oral)
The predictive role of signaling networks in advanced lung cancer: translational and clinical perspectives
Rafael Rosell M.D PhD
ASEICA Annual Congress, Salamanca, Spain, September 2011
(Invited lecture)
Nuevas Perspectivas tras la 14º Conferencia Mundial de Cáncer de Pulmón
Rafael Rosell M.D PhD
Post-Mundial de Cáncer de Pulmón, Madrid, September 2011
(Invited lecture)
Cancer management and the BREC trials
Rafael Rosell M.D PhD
Drum Tower Hospital, Nanjing, China, September 2011
(Invited lecture)
Recent advances in non-small cell lung cancer treatment
Rafael Rosell M.D PhD
Molecular Lung Cancer Symposium, Incheon, South Korea, September 2011
(Invited lecture)
K-ras Biology
Rafael Rosell M.D PhD
IASLC 14th World Conference on Lung Cancer (WCLC), Amsterdam, The Netherlands, July 2011
(Invited lecture)
Detection in Blood/Serum
Miquel Tarón PhD
IASLC 14th World Conference on Lung Cancer, Amsterdam (WCLC), The Netherlands, July 2011
(Invited lecture)
An open label, randomized phase II study evaluating dalotuzumab combined with erlotinib in patients with non-small cell lung cancer following failure of prior chemotherap
Rafael Rosell M.D PhD
IASLC 14th World Conference on Lung Cancer (WCLC), Amsterdam, The Netherlands, July 2011
(Oral)
Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations
Rafael Rosell M.D PhD
IASLC 14th World Conference on Lung Cancer (WCLC), Amsterdam, The Netherlands, July 2011
(Mini Oral)
Influence of BRCA1 and astrocyte elevated gene-1 as identified by multiplex target profiling of gene expression on outcome in erlotinib-treated non-small-cell lung cancer patients harboring EGFR mutations
Miquel Tarón PhD
IASLC 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 2011
(Mini Oral)
Erlotinib vs chemotherapy in advanced non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) activating mutations: Interim results of the European Tarceva® vs Chemotherapy (EURTAC) phase III randomized trial
Rafael Rosell M.D PhD
ASCO Annual Meeting, Chicago, U.S.A, June 2011
(Oral)
LKB1 mutation in non-small cell lung cancer
Rafael Rosell M.D PhD
IASLC/ASCO/ESMO 5th International Conference on Molecular Targeted Therapy in Lung Cancer, Malta, April 2011
(Invited lecture)
NanoString multiple target profiling identifies AEG-1 as an essential predictor of erlotinib outcome in EGFR-mutant non-small cell lung cancer
Miquel Tarón PhD
AACR 102nd Annual Meeting 2011, Orlando, Florida, U.S.A, April 2011
(Poster)
Translational lung cancer research in current practice: Benefit for patients
Rafael Rosell M.D PhD
II Curso Avances en el Abordaje Multidisciplinario del Cáncer de Pulmón Hospital Universitario Puerta de Hierro Majadahonda, Madrid, March 2011
(Invited lecture)
¿Hacia dónde debemos orientar la investigación en la neoadyuvancia?
Rafael Rosell M.D PhD
1er Simposio de Tratamiento de Inducción en Cáncer de Pulmón, Lledia, Spain, March 2011
(Keynote lecture)
Chemotherapy selection according to chemotherapy markers
Rafael Rosell M.D PhD
ESMO European Multidisciplinary Conference in Thoracic Oncology (EMCTO)
Lugano, Switzerland, February 2011
(Invited lecture)
Presentation and discussion of the Lugano Consensus: Pathology and molecular testing
Rafael Rosell M.D PhD
ESMO European Multidisciplinary Conference in Thoracic Oncology (EMCTO), Lugano, Switzerland, February 2011
(Invited lecture)
New tools in the molecular diagnostic of lung cancer
Miquel Tarón PhD
ESMO European Multidisciplinary Conference in Thoracic Oncology (EMCTO) Lugano, Switzerland, February 2011
(Invited lecture)
The evolving management of EGFR addicted lung cancer
Rafael Rosell M.D PhD
22nd International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 2011
(Invited lecture and Chair)
Customized treatment in NSCLC
Rafael Rosell M.D PhD
22nd International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 2011
(Invited lecture)
Growth factor signalling and DNA repair
Rafael Rosell M.D PhD
9th Annual British Thoracic Oncology Group Conference, Dublin, Ireland, January 2011
(Invited lecture)
Erlotinib in the management of NSCLC with mutated EGFR: the relevance of the OPTIMAL study
Rafael Rosell M.D PhD
Inspired V
Lisbon, Portugal, January 2011
(Invited lecture)
The predictive role of signaling networks involved in lung cancer
Rafael Rosell M.D PhD
CURELUNG Kick-off Meeting
Barcelona, Spain, January 2011
(Invited lecture)
Promising newer markers including EML4-ALK
Rafael Rosell M.D PhD
10th Nordic Lung Cancer Symposium
Copenhagen, Denmark, January 2011
(Invited lecture)